Duloxetin Krka 30 mg Noruega - noruego - Statens legemiddelverk

duloxetin krka 30 mg

krka sverige ab - duloksetinhydroklorid - enterokapsel, hard - 30 mg

Methylphenidate Teva 60 mg Noruega - noruego - Statens legemiddelverk

methylphenidate teva 60 mg

teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 60 mg

Methylphenidate Teva 10 mg Noruega - noruego - Statens legemiddelverk

methylphenidate teva 10 mg

teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 10 mg

Methylphenidate Teva 20 mg Noruega - noruego - Statens legemiddelverk

methylphenidate teva 20 mg

teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 20 mg

Methylphenidate Teva 30 mg Noruega - noruego - Statens legemiddelverk

methylphenidate teva 30 mg

teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 30 mg

Methylphenidate Teva 40 mg Noruega - noruego - Statens legemiddelverk

methylphenidate teva 40 mg

teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 40 mg

Sutent Unión Europea - noruego - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Temomedac Unión Europea - noruego - EMA (European Medicines Agency)

temomedac

medac gesellschaft für klinische spezialpräparate mbh - temozolomid - glioma; glioblastoma - antineoplastiske midler - temomedac harde kapsler er angitt for behandling av:voksne pasienter med nydiagnostisert glioblastoma multiforme samtidig med strålebehandling (rt) og senere som monoterapi til behandling;barn fra en alder av tre år, unge og voksne pasienter med ondartet glioma, slik som glioblastoma multiforme eller anaplastic astrocytom, viser tilbakefall eller progresjon etter standard terapi.

Miglustat Bluefish 100 mg Noruega - noruego - Statens legemiddelverk

miglustat bluefish 100 mg

bluefish pharmaceuticals ab - miglustat - kapsel, hard - 100 mg

Mykofenolat Accord 250 mg Noruega - noruego - Statens legemiddelverk

mykofenolat accord 250 mg

accord healthcare b.v. - mykofenolatmofetil - kapsel, hard - 250 mg